Sign In
Buy VNRX
$2.08
-0.240 (-10.34%)
At Close: Jun 03, 2026
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
04:12pm, Wednesday, 25'th Mar 2026
Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
Volition Announces Detection of Over 95% of Early-Stage Cancers
08:17am, Wednesday, 25'th Mar 2026
Blinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificity Capture-Seq™ Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
08:17am, Wednesday, 18'th Mar 2026
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
08:10am, Friday, 06'th Mar 2026
HENDERSON, Nev., March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verific
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
08:10am, Wednesday, 25'th Feb 2026
HENDERSON, Nev., Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the signifi
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
08:07am, Tuesday, 10'th Feb 2026
HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laborator
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
05:20pm, Monday, 09'th Feb 2026
HENDERSON, Nev., Feb. 9, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6, 2026, it
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
08:45am, Wednesday, 04'th Feb 2026
Showing New Indication for Nu.Q® NETs HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponso
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
08:50am, Friday, 30'th Jan 2026
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submiss
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
08:00am, Tuesday, 27'th Jan 2026
Nu.Q® Biomarker Paper Available on MedRXIV HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the r
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
08:25am, Tuesday, 20'th Jan 2026
HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory
Volition Sponsors Symposium at Veterinary Meeting and Expo
08:45am, Friday, 16'th Jan 2026
HENDERSON, Nev., Jan. 16, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an industry symposium at the wo
VolitionRx Secures $2.0 Million in Funding
09:15am, Thursday, 08'th Jan 2026
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
08:45am, Thursday, 08'th Jan 2026
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epi
Volition Issues Business Review 2025
08:45am, Wednesday, 17'th Dec 2025
HENDERSON, Nev. , Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025.
